Thymoma: A population-based study of the management and outcomes for the province of British Columbia

Journal of Thoracic Oncology

Volumn 8, Issue 1, 2013, Pages 109-117

  Mariano, Caroline ^a   Ionescu, Diana N ^a   Cheung, Winson Y ^a   Ali, Rola H ^a   Laskin, Janessa ^a   Evans, Ken ^b   Carolan, Hannah ^a   Murray, Nevin ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Outcomes; Population; Thymic carcinoma; Thymoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; OCTREOTIDE; PREDNISONE;

ADULT; ADVANCED CANCER; AGED; CANADA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE SEVERITY; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARANEOPLASTIC SYNDROME; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THYMECTOMY; THYMOMA; THYMUS CANCER;

EID: 84871980632     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318276241c     Document Type: Article

References (28)

1. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003;105:546-551.
2. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5(10 Suppl 4):S260-S265.
3. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic clas-sifcation is a prognostic indicator in thymoma. Ann Thorac Surg 2004;77:1183-1188.
4. Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma: a clinicopatho-logic study based on the new World Health Organization classifcation. J Thorac Cardiovasc Surg 2003;126:1134-1140.
5. Moran CA, Walsh G, Suster S, Kaiser L. Thymomas II: a clinicopath-ologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment. Am J Clin Pathol 2012;137:451-461.
6. Gamondès J P, Balawi A, Greenland T, et al. Seventeen years of surgical treatment of thymoma: factors infuencing survival. Eur J Cardiothorac Surg 1991;5:124-131.
7. Fuller CD, Ramahi EH, Aherne N, Eng TY, Thomas CR Jr. Radiotherapy for thymic neoplasms. J Thorac Oncol 2010;5(10 Suppl 4):S327-S335.
8. Yokoi K, Matsuguma H, Nakahara R, et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methyl-prednisolone. J Thorac Oncol 2007;2:73-78.
9. Venuta F, Rendina EA, Coloni G F. Multimodality treatment of thymic tumors. Thorac Surg Clin 2009;19:71-81.
10. Bretti S, Berruti A, Loddo C, et al.; Piemonte Oncology Network. Multimodal management of stages III-IVa malignant thymoma. Lung Cancer 2004;44:69-77.
11. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008;44:123-130.
12. Mariusdottir E, Nikulasson S, Bjornsson J, Gudbjartsson T. Thymic epithelial tumours in Iceland: incidence and histopathology, a population-based study. APMIS 2010;118:927-933.
13. Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr. Standard outcome measures for thymic malignancies. J Thorac Oncol 2010;5:2017-2023.
14. Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classifcation for thymic malignancies: clarifcation and defnition of terms. J Thorac Oncol 2011;6(Suppl 3):S1710-S1716.
15. Chen G, Marx A, Chen WH, et al. New WHO histologic classifcation predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95:420-429.
16. Gadalla SM, Rajan A, Pfeiffer R, et al. A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer 2011;128:2688-2694.
17. Weksler B, Nason KS, Mackey D, Gallagher A, Pennathur A. Thymomas and extrathymic cancers. Ann Thorac Surg 2012;93:884-888.
18. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1, 320 patients from Japan. Ann Thorac Surg. 2003;76:878-84; discussion 884-885.
19. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-2492.
20. Berman AT, Litzky L, Livolsi V, et al. Adjuvant radiotherapy for completely resected stage 2 thymoma. Cancer 2011;117:3502-3508.
21. Fernandes AT, Shinohara ET, Guo M, et al. The role of radiation therapy in malignant thymoma: a Surveillance, Epidemiology, and End Results database analysis. J Thorac Oncol 2010;5:1454-1460.
22. Fuller CD, Housman DM, Thomas CR. Radiotherapy for thymoma and thymic carcinoma. Hematol Oncol Clin North Am 2008;22:489-507.
23. Falkson CB, Bezjak A, Darling G, et al.; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009;4:911-919.
24. Lucchi M, Melf F, Dini P, et al. Neoadjuvant chemotherapy for stage III and I VA thymomas: a single-institution experience with a long follow-up. J Thorac Oncol 2006;1:308-313.
25. Hassan M, Seoud DE. Multimodality treatments in locally advanced stage thymomas. Hematol Oncol Stem Cell Ther 2009;2:340-344.
26. Spaggiari L, Casiraghi M, Guarize J. Multidisciplinary treatment of malignant thymoma. Curr Opin Oncol 2012;24:117-122.
27. Albain KS, Swann RS, Rusch V W, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-386.
28. Detterbeck F. International thymic malignancies interest group: a way forward. J Thorac Oncol. 2010;5:S365-70.